Biography and Research Information
OverviewAI-generated summary
Divaya Bhutani's research focuses on the treatment and outcomes of hematologic malignancies, particularly multiple myeloma and immunoglobulin light-chain amyloidosis. Her work investigates the efficacy and safety of novel therapeutic agents, including monoclonal antibodies like daratumumab and teclistamab, as well as targeted therapies such as venetoclax and pembrolizumab.
Bhutani has published extensively on these topics, with recent work exploring the use of daratumumab-based regimens in front-line therapy for AL amyloidosis and the impact of bispecific antibody therapy on infection spectrum in relapsed refractory multiple myeloma. Her collaborations include work with Maurizio Zangari, Sharmilan Thanendrarajan, Frits van Rhee, and Samer Al Hadidi, all at the University of Arkansas for Medical Sciences, contributing to a collective understanding of these complex diseases. Her scholarship metrics include an h-index of 25, with 183 total publications and 2,670 citations, designating her as a highly cited researcher.
Metrics
- h-index: 25
- Publications: 183
- Citations: 2,670
Selected Publications
-
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study (2025)
Collaboration Network
Top Collaborators
- Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Similar Researchers
Based on overlapping research topics